Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 276 participants.
Also called NCT04263038
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 276 participants
- Registry
-
NCT04263038
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Belgium, Canada, France, Netherlands, Switzerland
- Registry status
- Recruiting
Technical summary
Registry record NCT04263038. Randomized; quadruple masking; primary purpose treatment. Start 2020-05-15 (actual); primary completion 2028-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
- Acronym
- SAFE-SSPE
- Condition
- Pulmonary Embolism
- Condition
- Embolism
- Condition
- Embolism and Thrombosis
- Condition
- Lung Diseases
- Condition
- Cardiovascular Diseases
- Condition
- Respiratory Tract Diseases
- Condition
- Venous Thromboembolism
- Condition
- Anticoagulant-induced Bleeding
- Condition
- Bleeding
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- Placebo
- Lead sponsor
- Drahomir Aujesky
- Collaborator
- University of Bern
- Collaborator
- Schweizerischer Nationalfonds
- Collaborator
- Leiden University Medical Center
- Collaborator
- The Ottawa Hospital
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct04263038- Content hash
b00baca0ee19635cd6bac35c136a504f9cf352e1393d371826522105ab9a8846